1. Home
  2. CAL vs CBIO Comparison

CAL vs CBIO Comparison

Compare CAL & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caleres Inc.

CAL

Caleres Inc.

HOLD

Current Price

$11.74

Market Cap

412.1M

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$16.86

Market Cap

482.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAL
CBIO
Founded
1878
2003
Country
United States
United States
Employees
N/A
44
Industry
Shoe Manufacturing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
412.1M
482.6M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
CAL
CBIO
Price
$11.74
$16.86
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$15.00
$26.67
AVG Volume (30 Days)
689.8K
313.1K
Earning Date
05-28-2026
04-29-2026
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$85,513,000.00
N/A
Revenue This Year
$5.19
N/A
Revenue Next Year
$2.45
$279.20
P/E Ratio
$27.88
N/A
Revenue Growth
0.46
N/A
52 Week Low
$8.80
$8.72
52 Week High
$16.14
$27.41

Technical Indicators

Market Signals
Indicator
CAL
CBIO
Relative Strength Index (RSI) 40.71 42.88
Support Level $10.69 $17.02
Resistance Level $11.88 $19.05
Average True Range (ATR) 0.81 1.26
MACD -0.18 -0.01
Stochastic Oscillator 1.49 21.77

Price Performance

Historical Comparison
CAL
CBIO

About CAL Caleres Inc.

Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: